mbiomics
Advancing scalable microbiome-based therapeutics for severe and chronic diseases.
About
mbiomics designs and develops complex Live Biotherapeutic Products (LBPs) to change the treatment paradigm of severe and chronic diseases. They leverage proprietary precision analytics and patient insights to build a pipeline of rationally selected microbial communities for indication-specific treatment. Their goal is to access the gut microbiome's full immunological and metabolic potential to restore healthy microbial ecosystems and overcome disease. Teams look it up for Biotechnology, Pharmaceuticals, Healthcare.
Frequently asked
What does mbiomics do?
mbiomics is a Biotechnology company that offers Platform. Teams look it up for Pharmaceuticals, Healthcare, Artificial Intelligence. It is based in Munich, Bavaria, Germany and was founded in 2020. Public records show $12M in total funding. Compare it on funding, headcount, reviews and nearby alternatives rather than the marketing line alone.
How much funding has mbiomics raised?
mbiomics has raised a total of $12M in funding. The most recent round on record is Series A.
Where is mbiomics headquartered?
mbiomics is headquartered in Munich, Bavaria, Germany.
When was mbiomics founded?
mbiomics was founded in 2020.
What industry does mbiomics operate in?
mbiomics operates in Biotechnology, Pharmaceuticals, Healthcare, Artificial Intelligence, Biotech.
Strength of the site’s backlink profile, on Ahrefs’ 0-100 Domain Rating scale. Licensed third-party data, not our opinion.
How well an AI agent can read and use this site: structured data, clean markup, and whether key facts are reachable without running JavaScript. We scan the live site.
Google PageSpeed mobile performance for the company’s own site. Measured by Google, not by us.